Animal Biotechnology Market by Product Type (Recombinant Proteins, Vaccines), Technology (Cell Culture, Genetic Engineering, PCR And DNA Sequencing), Application, End-User - Global Forecast 2025-2032
Description
The Animal Biotechnology Market was valued at USD 31.04 billion in 2024 and is projected to grow to USD 33.81 billion in 2025, with a CAGR of 8.71%, reaching USD 60.56 billion by 2032.
A forward-looking introduction framing how converging biotechnologies, regulatory priorities, and operational scale are reshaping animal health innovation pathways
The animal biotechnology sector is at an inflection point driven by converging advances in molecular biology, biomanufacturing, and livestock management practices. Recent improvements in gene editing precision, the maturation of cell culture processes for nontraditional hosts, and the proliferation of high-throughput sequencing have collectively expanded the range of viable interventions for animal health, nutrition, and productivity. Meanwhile, heightened regulatory attention to traceability, biosecurity, and One Health considerations has elevated the importance of rigorous validation and quality systems across development pathways.
Against this backdrop, stakeholders from research laboratories to pharmaceutical investors face a dual imperative: accelerate innovation while demonstrating reproducible safety and efficacy. This requires a strategic balancing of internal capabilities and external partnerships; contract research organizations and specialized manufacturers play an increasingly central role in translating laboratory discoveries into deployable products. As technologies such as recombinant proteins, novel vaccine platforms, and PCR‑based diagnostics move from proof of concept to scalable products, the industry’s ability to integrate regulatory foresight, supply chain resilience, and operational scalability will determine which initiatives progress to commercial impact.
How data-driven biology, modular biomanufacturing, and evolving regulatory frameworks are recalibrating innovation, development, and commercialization strategies
Transformative shifts are redefining what is possible in animal biotechnology and are changing how stakeholders prioritize investment and capability development. At the core is a shift from ingredient- and empirically driven approaches toward mechanistic, data-driven strategies enabled by next-generation sequencing and advanced bioinformatics. This transition empowers developers to design vaccines and therapeutics with improved antigen specificity, to optimize feed enzyme profiles for targeted nutritional outcomes, and to accelerate candidate selection in drug discovery.
Concurrently, biomanufacturing is becoming more modular and flexible; single-use systems, process intensification, and geographically distributed production models reduce capital barriers and lower lead times. Regulatory frameworks are evolving in parallel to accommodate platform technologies such as DNA vaccines and gene-edited products, although the pace and nature of regulatory change vary regionally. Finally, commercial models are shifting toward partnerships and service-based structures, where contract research organizations and contract development and manufacturing organizations collaborate closely with innovators to derisk product development and shorten timelines to deployment.
Assessing how recent tariff and trade policy adjustments have reshaped procurement strategies, supplier diversification, and manufacturing footprint decisions across the value chain
Policy measures introduced in 2025 relating to tariffs and trade have introduced a new set of considerations for supply chain planning and cost allocation in animal biotechnology value chains. Tariff adjustments on key instrument components, biological reagents, and certain manufactured goods have elevated the importance of sourcing strategies, inventory buffers, and nearshoring evaluations. In response, many organizations have revisited supplier diversification and contingency planning to mitigate exposure to import duties that can unpredictably affect reagent and consumable cost bases.
At the same time, the tariff landscape has prompted strategic reassessments of manufacturing footprints and procurement policies. Some developers have accelerated qualification of alternative suppliers and validated parallel supply streams for critical inputs such as polymerases, cell culture media components, and single-use consumables. Others have explored local contract manufacturing partnerships to reduce cross-border friction. Importantly, these operational shifts are not only cost driven; they also reflect a heightened emphasis on supply assurance, regulatory alignment for imported materials, and the need to maintain uninterrupted R&D and production schedules amidst evolving trade policies.
Practical segmentation-driven intelligence that links product types, enabling technologies, and application pathways to end-user dynamics for informed portfolio prioritization
Segmentation-based insights provide a practical framework for aligning R&D and commercial strategies with distinct development complexities and market dynamics. When evaluating product types, recombinant proteins and vaccines present different technical and regulatory pathways; recombinant proteins include antibodies, enzymes, and growth hormones, where enzymes subdivide into lipases, phytases, and proteases, and vaccines span DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. These delineations influence choices around upstream expression systems, downstream purification workflows, and stability profiles, and they inform investments in analytical and quality control capabilities.
Technology segmentation further clarifies capability needs: cell culture platforms, genetic engineering tools, and PCR and DNA sequencing methods define core technical competencies. Within cell culture, avian, insect, and mammalian systems each offer distinct tradeoffs in post-translational modification, yield, and regulatory familiarity. Genetic engineering activities include gene editing, gene synthesis, and transgenic technologies, which drive target selection and construct design. PCR and DNA sequencing encompass next-generation sequencing, PCR kits, and Sanger sequencing, underpinning diagnostic development and genomic surveillance.
Application-driven segmentation differentiates pathway priorities for diagnostics, drug discovery, and feed additives. Diagnostic workflows rely on ELISA kits, lateral flow assays, and PCR-based tests that demand rapid validation and robust supply chains, whereas drug discovery emphasizes lead optimization, preclinical testing, and target identification with significant upstream investment in models and analytics. Feed additive development leverages carbohydrases, phytases, and proteases to deliver nutritional and performance outcomes. Finally, end-user segmentation-the split across animal farms, contract research organizations, pharmaceutical companies, and research laboratories-illuminates commercialization channels, adoption patterns, and support service requirements that should inform go-to-market planning.
Regional differentiation in regulatory frameworks, manufacturing capabilities, and adoption drivers that inform localized strategies for market entry and scale-up
Regional dynamics shape regulatory requirements, adoption velocity, and partnership opportunities across animal biotechnology ecosystems. The Americas combine advanced research infrastructure with a diverse mix of large-scale animal agriculture and biotech clusters, supporting rapid translation from discovery to manufacturing while prioritizing strong regulatory oversight and quality systems. Europe, Middle East & Africa presents a mosaic of regulatory regimes and market needs; while some markets emphasize stringent safety and traceability standards, others prioritize accessibility and affordability, driving differentiated product strategies across the region. Asia-Pacific displays a spectrum from high-capacity manufacturing hubs and intensive livestock systems to emerging markets with growing demand for diagnostics, vaccines, and feed improvements.
These geographic differences affect choices around clinical trial design, manufacturing location, and commercial partnerships. For example, developers targeting broad adoption must reconcile heterogeneous regulatory expectations and tailor data packages to regional authorities. In addition, regional supply chain resilience considerations-such as logistics, warehousing, and access to critical raw materials-inform decisions about localized production versus centralized manufacturing. Strategic entrants and incumbents alike benefit from aligning regional regulatory intelligence with operational planning to optimize product registries, distribution networks, and stakeholder engagement strategies.
How competitive positioning, platform investments, and strategic partnerships are defining corporate success and resilience in the evolving animal biotechnology ecosystem
Competitive dynamics in animal biotechnology are characterized by a diverse mix of established biotechnology and pharmaceutical firms, specialized contract development and manufacturing organizations, diagnostic innovators, and agile startups focused on niche technical advances. Leading players tend to concentrate investments in platform technologies that provide repeatable development advantages across recombinant proteins, vaccines, and diagnostics, while smaller specialists often compete on speed, niche expertise, or cost-efficient manufacturing modalities. Cross-sector partnerships between feed additive developers and animal health companies are also increasingly common, reflecting convergence between nutrition and immunological interventions.
Key corporate strategies include vertical integration of manufacturing capabilities to secure quality and supply, strategic alliances with contract research organizations to accelerate candidate validation, and licensing agreements that enable portfolio expansion without excessive capital expenditure. Companies that excel in rigorous quality management, scalable process development, and regulatory strategy demonstrate higher resilience when navigating approval pathways and adapting to policy shifts. Moreover, intellectual property stewardship and transparent data packages are critical for maintaining competitive differentiation while enabling collaborative models that advance platform adoption across the ecosystem.
Actionable recommendations that blend strategic partnerships, modular manufacturing, and regulatory engagement to accelerate innovation while managing operational risk
Industry leaders should pursue an integrated set of actions that balance innovation velocity with operational resilience and regulatory preparedness. Strengthening supplier diversification and validating parallel sourcing for critical reagents and consumables will reduce exposure to trade policy shocks and inventory disruptions; concurrently, investing in scalable, modular manufacturing approaches can accelerate response times and enable regional production where regulatory alignment and logistics favor local supply. Leaders should also prioritize platform technologies that deliver repeatable value across multiple product types, enabling economies of scale in analytics, process development, and quality control.
From a development standpoint, aligning early regulatory engagement with robust data generation-particularly for novel modalities such as DNA vaccines and gene-edited therapeutics-reduces downstream uncertainty and shortens time to market readiness. Cultivating strategic partnerships with contract research organizations, academic centers, and feed or livestock integrators can bridge capability gaps and facilitate real-world validation studies. Finally, embedding digital tools for data management, traceability, and predictive maintenance enhances decision-making and supports continuous improvement efforts across R&D and manufacturing operations.
A transparent, mixed-methods research approach combining expert interviews, literature synthesis, and data triangulation to validate findings and account for uncertainties
The research methodology relied on a mixed-methods approach integrating both primary and secondary inputs to ensure analytical rigor and contextual relevance. Primary research included structured interviews with subject-matter experts across research laboratories, contract organizations, manufacturers, and regulatory affairs professionals, supplemented by validation conversations with technology providers and end users. These dialogues informed qualitative assessments of technology readiness, supply chain vulnerabilities, and adoption barriers.
Secondary research encompassed a comprehensive review of peer-reviewed literature, regulatory guidance documents, patent landscapes, and publicly available technical disclosures to ground findings in documented evidence. Data triangulation techniques were applied to reconcile differing perspectives and to stress-test assumptions. Analytical frameworks included capability mapping, scenario analysis for policy impacts, and comparative assessments of platform maturity. Importantly, the methodology emphasized transparency about data sources and limitations, enabling stakeholders to interpret outcomes within the appropriate context and to request clarifications or deeper dives as needed.
A concise conclusion that synthesizes technological advances, operational priorities, and strategic imperatives for translating innovation into impact
In summary, the animal biotechnology landscape is advancing rapidly as innovations in genetic engineering, cell culture, and molecular diagnostics converge with changing regulatory expectations and commercial models. Successful organizations will be those that couple technological differentiation with operational adaptability-investing in platform capabilities that can be deployed across recombinant proteins, vaccines, diagnostics, and feed additives while maintaining rigorous quality and regulatory alignment. Supply chain resilience and strategic partnerships will continue to be critical levers for mitigating trade and tariff-induced risk and for accelerating progression from lab to field.
As the sector evolves, decision makers should focus on building cross-functional competencies that integrate scientific excellence with manufacturing pragmatism and market insight. Long-term value will be created by entities that are able to rapidly validate efficacy and safety, scale production responsibly, and tailor deployment strategies to regional regulatory and commercial realities. By doing so, stakeholders can translate scientific breakthroughs into practical solutions that enhance animal health, bolster productivity, and contribute to broader public and economic health objectives.
Please Note: PDF & Excel + Online Access - 1 Year
A forward-looking introduction framing how converging biotechnologies, regulatory priorities, and operational scale are reshaping animal health innovation pathways
The animal biotechnology sector is at an inflection point driven by converging advances in molecular biology, biomanufacturing, and livestock management practices. Recent improvements in gene editing precision, the maturation of cell culture processes for nontraditional hosts, and the proliferation of high-throughput sequencing have collectively expanded the range of viable interventions for animal health, nutrition, and productivity. Meanwhile, heightened regulatory attention to traceability, biosecurity, and One Health considerations has elevated the importance of rigorous validation and quality systems across development pathways.
Against this backdrop, stakeholders from research laboratories to pharmaceutical investors face a dual imperative: accelerate innovation while demonstrating reproducible safety and efficacy. This requires a strategic balancing of internal capabilities and external partnerships; contract research organizations and specialized manufacturers play an increasingly central role in translating laboratory discoveries into deployable products. As technologies such as recombinant proteins, novel vaccine platforms, and PCR‑based diagnostics move from proof of concept to scalable products, the industry’s ability to integrate regulatory foresight, supply chain resilience, and operational scalability will determine which initiatives progress to commercial impact.
How data-driven biology, modular biomanufacturing, and evolving regulatory frameworks are recalibrating innovation, development, and commercialization strategies
Transformative shifts are redefining what is possible in animal biotechnology and are changing how stakeholders prioritize investment and capability development. At the core is a shift from ingredient- and empirically driven approaches toward mechanistic, data-driven strategies enabled by next-generation sequencing and advanced bioinformatics. This transition empowers developers to design vaccines and therapeutics with improved antigen specificity, to optimize feed enzyme profiles for targeted nutritional outcomes, and to accelerate candidate selection in drug discovery.
Concurrently, biomanufacturing is becoming more modular and flexible; single-use systems, process intensification, and geographically distributed production models reduce capital barriers and lower lead times. Regulatory frameworks are evolving in parallel to accommodate platform technologies such as DNA vaccines and gene-edited products, although the pace and nature of regulatory change vary regionally. Finally, commercial models are shifting toward partnerships and service-based structures, where contract research organizations and contract development and manufacturing organizations collaborate closely with innovators to derisk product development and shorten timelines to deployment.
Assessing how recent tariff and trade policy adjustments have reshaped procurement strategies, supplier diversification, and manufacturing footprint decisions across the value chain
Policy measures introduced in 2025 relating to tariffs and trade have introduced a new set of considerations for supply chain planning and cost allocation in animal biotechnology value chains. Tariff adjustments on key instrument components, biological reagents, and certain manufactured goods have elevated the importance of sourcing strategies, inventory buffers, and nearshoring evaluations. In response, many organizations have revisited supplier diversification and contingency planning to mitigate exposure to import duties that can unpredictably affect reagent and consumable cost bases.
At the same time, the tariff landscape has prompted strategic reassessments of manufacturing footprints and procurement policies. Some developers have accelerated qualification of alternative suppliers and validated parallel supply streams for critical inputs such as polymerases, cell culture media components, and single-use consumables. Others have explored local contract manufacturing partnerships to reduce cross-border friction. Importantly, these operational shifts are not only cost driven; they also reflect a heightened emphasis on supply assurance, regulatory alignment for imported materials, and the need to maintain uninterrupted R&D and production schedules amidst evolving trade policies.
Practical segmentation-driven intelligence that links product types, enabling technologies, and application pathways to end-user dynamics for informed portfolio prioritization
Segmentation-based insights provide a practical framework for aligning R&D and commercial strategies with distinct development complexities and market dynamics. When evaluating product types, recombinant proteins and vaccines present different technical and regulatory pathways; recombinant proteins include antibodies, enzymes, and growth hormones, where enzymes subdivide into lipases, phytases, and proteases, and vaccines span DNA vaccines, inactivated vaccines, live attenuated vaccines, and subunit vaccines. These delineations influence choices around upstream expression systems, downstream purification workflows, and stability profiles, and they inform investments in analytical and quality control capabilities.
Technology segmentation further clarifies capability needs: cell culture platforms, genetic engineering tools, and PCR and DNA sequencing methods define core technical competencies. Within cell culture, avian, insect, and mammalian systems each offer distinct tradeoffs in post-translational modification, yield, and regulatory familiarity. Genetic engineering activities include gene editing, gene synthesis, and transgenic technologies, which drive target selection and construct design. PCR and DNA sequencing encompass next-generation sequencing, PCR kits, and Sanger sequencing, underpinning diagnostic development and genomic surveillance.
Application-driven segmentation differentiates pathway priorities for diagnostics, drug discovery, and feed additives. Diagnostic workflows rely on ELISA kits, lateral flow assays, and PCR-based tests that demand rapid validation and robust supply chains, whereas drug discovery emphasizes lead optimization, preclinical testing, and target identification with significant upstream investment in models and analytics. Feed additive development leverages carbohydrases, phytases, and proteases to deliver nutritional and performance outcomes. Finally, end-user segmentation-the split across animal farms, contract research organizations, pharmaceutical companies, and research laboratories-illuminates commercialization channels, adoption patterns, and support service requirements that should inform go-to-market planning.
Regional differentiation in regulatory frameworks, manufacturing capabilities, and adoption drivers that inform localized strategies for market entry and scale-up
Regional dynamics shape regulatory requirements, adoption velocity, and partnership opportunities across animal biotechnology ecosystems. The Americas combine advanced research infrastructure with a diverse mix of large-scale animal agriculture and biotech clusters, supporting rapid translation from discovery to manufacturing while prioritizing strong regulatory oversight and quality systems. Europe, Middle East & Africa presents a mosaic of regulatory regimes and market needs; while some markets emphasize stringent safety and traceability standards, others prioritize accessibility and affordability, driving differentiated product strategies across the region. Asia-Pacific displays a spectrum from high-capacity manufacturing hubs and intensive livestock systems to emerging markets with growing demand for diagnostics, vaccines, and feed improvements.
These geographic differences affect choices around clinical trial design, manufacturing location, and commercial partnerships. For example, developers targeting broad adoption must reconcile heterogeneous regulatory expectations and tailor data packages to regional authorities. In addition, regional supply chain resilience considerations-such as logistics, warehousing, and access to critical raw materials-inform decisions about localized production versus centralized manufacturing. Strategic entrants and incumbents alike benefit from aligning regional regulatory intelligence with operational planning to optimize product registries, distribution networks, and stakeholder engagement strategies.
How competitive positioning, platform investments, and strategic partnerships are defining corporate success and resilience in the evolving animal biotechnology ecosystem
Competitive dynamics in animal biotechnology are characterized by a diverse mix of established biotechnology and pharmaceutical firms, specialized contract development and manufacturing organizations, diagnostic innovators, and agile startups focused on niche technical advances. Leading players tend to concentrate investments in platform technologies that provide repeatable development advantages across recombinant proteins, vaccines, and diagnostics, while smaller specialists often compete on speed, niche expertise, or cost-efficient manufacturing modalities. Cross-sector partnerships between feed additive developers and animal health companies are also increasingly common, reflecting convergence between nutrition and immunological interventions.
Key corporate strategies include vertical integration of manufacturing capabilities to secure quality and supply, strategic alliances with contract research organizations to accelerate candidate validation, and licensing agreements that enable portfolio expansion without excessive capital expenditure. Companies that excel in rigorous quality management, scalable process development, and regulatory strategy demonstrate higher resilience when navigating approval pathways and adapting to policy shifts. Moreover, intellectual property stewardship and transparent data packages are critical for maintaining competitive differentiation while enabling collaborative models that advance platform adoption across the ecosystem.
Actionable recommendations that blend strategic partnerships, modular manufacturing, and regulatory engagement to accelerate innovation while managing operational risk
Industry leaders should pursue an integrated set of actions that balance innovation velocity with operational resilience and regulatory preparedness. Strengthening supplier diversification and validating parallel sourcing for critical reagents and consumables will reduce exposure to trade policy shocks and inventory disruptions; concurrently, investing in scalable, modular manufacturing approaches can accelerate response times and enable regional production where regulatory alignment and logistics favor local supply. Leaders should also prioritize platform technologies that deliver repeatable value across multiple product types, enabling economies of scale in analytics, process development, and quality control.
From a development standpoint, aligning early regulatory engagement with robust data generation-particularly for novel modalities such as DNA vaccines and gene-edited therapeutics-reduces downstream uncertainty and shortens time to market readiness. Cultivating strategic partnerships with contract research organizations, academic centers, and feed or livestock integrators can bridge capability gaps and facilitate real-world validation studies. Finally, embedding digital tools for data management, traceability, and predictive maintenance enhances decision-making and supports continuous improvement efforts across R&D and manufacturing operations.
A transparent, mixed-methods research approach combining expert interviews, literature synthesis, and data triangulation to validate findings and account for uncertainties
The research methodology relied on a mixed-methods approach integrating both primary and secondary inputs to ensure analytical rigor and contextual relevance. Primary research included structured interviews with subject-matter experts across research laboratories, contract organizations, manufacturers, and regulatory affairs professionals, supplemented by validation conversations with technology providers and end users. These dialogues informed qualitative assessments of technology readiness, supply chain vulnerabilities, and adoption barriers.
Secondary research encompassed a comprehensive review of peer-reviewed literature, regulatory guidance documents, patent landscapes, and publicly available technical disclosures to ground findings in documented evidence. Data triangulation techniques were applied to reconcile differing perspectives and to stress-test assumptions. Analytical frameworks included capability mapping, scenario analysis for policy impacts, and comparative assessments of platform maturity. Importantly, the methodology emphasized transparency about data sources and limitations, enabling stakeholders to interpret outcomes within the appropriate context and to request clarifications or deeper dives as needed.
A concise conclusion that synthesizes technological advances, operational priorities, and strategic imperatives for translating innovation into impact
In summary, the animal biotechnology landscape is advancing rapidly as innovations in genetic engineering, cell culture, and molecular diagnostics converge with changing regulatory expectations and commercial models. Successful organizations will be those that couple technological differentiation with operational adaptability-investing in platform capabilities that can be deployed across recombinant proteins, vaccines, diagnostics, and feed additives while maintaining rigorous quality and regulatory alignment. Supply chain resilience and strategic partnerships will continue to be critical levers for mitigating trade and tariff-induced risk and for accelerating progression from lab to field.
As the sector evolves, decision makers should focus on building cross-functional competencies that integrate scientific excellence with manufacturing pragmatism and market insight. Long-term value will be created by entities that are able to rapidly validate efficacy and safety, scale production responsibly, and tailor deployment strategies to regional regulatory and commercial realities. By doing so, stakeholders can translate scientific breakthroughs into practical solutions that enhance animal health, bolster productivity, and contribute to broader public and economic health objectives.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
191 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Emergence of CRISPR/Cas9 gene editing to enhance disease resistance in poultry farming operations
- 5.2. Commercial scale adoption of cell cultured meat production to reduce environmental impact and meet consumer demand
- 5.3. Integration of artificial intelligence and genomics data for predictive health management in dairy cattle herds
- 5.4. Advances in microbiome modulation therapies to improve feed efficiency and disease resilience in swine
- 5.5. Deployment of recombinant vaccine platforms to control emerging zoonotic diseases in livestock industries
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Animal Biotechnology Market, by Product Type
- 8.1. Recombinant Proteins
- 8.1.1. Antibodies
- 8.1.2. Enzymes
- 8.1.2.1. Lipases
- 8.1.2.2. Phytases
- 8.1.2.3. Proteases
- 8.1.3. Growth Hormones
- 8.2. Vaccines
- 8.2.1. DNA Vaccines
- 8.2.2. Inactivated Vaccines
- 8.2.3. Live Attenuated Vaccines
- 8.2.4. Subunit Vaccines
- 9. Animal Biotechnology Market, by Technology
- 9.1. Cell Culture
- 9.1.1. Avian Cell Culture
- 9.1.2. Insect Cell Culture
- 9.1.3. Mammalian Cell Culture
- 9.2. Genetic Engineering
- 9.2.1. Gene Editing
- 9.2.2. Gene Synthesis
- 9.2.3. Transgenic Technology
- 9.3. PCR And DNA Sequencing
- 9.3.1. Next-Generation Sequencing
- 9.3.2. PCR Kits
- 9.3.3. Sanger Sequencing
- 10. Animal Biotechnology Market, by Application
- 10.1. Diagnostics
- 10.1.1. ELISA Kits
- 10.1.2. Lateral Flow Assays
- 10.1.3. PCR-Based Tests
- 10.2. Drug Discovery
- 10.2.1. Lead Optimization
- 10.2.2. Preclinical Testing
- 10.2.3. Target Identification
- 10.3. Feed Additives
- 10.3.1. Carbohydrases
- 10.3.2. Phytases
- 10.3.3. Proteases
- 11. Animal Biotechnology Market, by End-User
- 11.1. Animal Farms
- 11.2. Contract Research Organizations
- 11.3. Pharmaceutical Companies
- 11.4. Research Laboratories
- 12. Animal Biotechnology Market, by Region
- 12.1. Americas
- 12.1.1. North America
- 12.1.2. Latin America
- 12.2. Europe, Middle East & Africa
- 12.2.1. Europe
- 12.2.2. Middle East
- 12.2.3. Africa
- 12.3. Asia-Pacific
- 13. Animal Biotechnology Market, by Group
- 13.1. ASEAN
- 13.2. GCC
- 13.3. European Union
- 13.4. BRICS
- 13.5. G7
- 13.6. NATO
- 14. Animal Biotechnology Market, by Country
- 14.1. United States
- 14.2. Canada
- 14.3. Mexico
- 14.4. Brazil
- 14.5. United Kingdom
- 14.6. Germany
- 14.7. France
- 14.8. Russia
- 14.9. Italy
- 14.10. Spain
- 14.11. China
- 14.12. India
- 14.13. Japan
- 14.14. Australia
- 14.15. South Korea
- 15. Competitive Landscape
- 15.1. Market Share Analysis, 2024
- 15.2. FPNV Positioning Matrix, 2024
- 15.3. Competitive Analysis
- 15.3.1. Zoetis Inc.
- 15.3.2. Merck & Co., Inc.
- 15.3.3. Elanco Animal Health Incorporated
- 15.3.4. Boehringer Ingelheim International GmbH
- 15.3.5. IDEXX Laboratories, Inc.
- 15.3.6. Ceva Santé Animale S.A.
- 15.3.7. Virbac S.A.
- 15.3.8. Vetoquinol S.A.
- 15.3.9. Dechra Pharmaceuticals plc
- 15.3.10. Phibro Animal Health Corporation
- 15.3.11. Neogen Corporation
- 15.3.12. Genus plc
- 15.3.13. Hendrix Genetics BV
- 15.3.14. Recombinetics, Inc.
- 15.3.15. Bio-Rad Laboratories, Inc.
- 15.3.16. Thermo Fisher Scientific Inc.
- 15.3.17. Trans Ova Genetics, LC
- 15.3.18. Animal Genetics, Inc.
- 15.3.19. HIPRA S.A.
- 15.3.20. Biogénesis Bagó S.A.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
